Q32 Bio Inc.
QTTB
$1.66
-$0.0001-0.01%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -14.66M | -12.80M | -9.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -14.66M | -12.80M | -9.60M |
| Cost of Revenue | 38.57M | 38.46M | 36.25M | 29.37M | 23.98M |
| Gross Profit | -38.57M | -38.46M | -50.92M | -42.17M | -33.57M |
| SG&A Expenses | 18.06M | 17.96M | 16.79M | 14.51M | 12.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.56M | 66.10M | 62.72M | 53.57M | 46.13M |
| Operating Income | -62.56M | -66.10M | -77.39M | -66.37M | -55.73M |
| Income Before Tax | -59.95M | -47.89M | -58.91M | -55.28M | -45.56M |
| Income Tax Expenses | -155.00K | -155.00K | 1.70M | 1.77M | 318.00K |
| Earnings from Continuing Operations | -59.79 | -47.73 | -60.61 | -57.05 | -45.88 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -59.79M | -47.73M | -60.61M | -57.05M | -45.88M |
| EBIT | -62.56M | -66.10M | -77.39M | -66.37M | -55.73M |
| EBITDA | -62.08M | -65.62M | -76.89M | -65.88M | -55.23M |
| EPS Basic | -4.95 | -3.01 | -78.22 | -117.29 | -132.56 |
| Normalized Basic EPS | -3.83 | -2.67 | -37.41 | -61.74 | -71.36 |
| EPS Diluted | -4.95 | -10.37 | -85.59 | -124.65 | -139.92 |
| Normalized Diluted EPS | -3.83 | -3.04 | -37.78 | -62.11 | -71.73 |
| Average Basic Shares Outstanding | 48.42M | 37.22M | 25.39M | 13.66M | 2.04M |
| Average Diluted Shares Outstanding | 48.42M | 38.56M | 26.73M | 15.00M | 3.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |